MLTX: MoonLake Immunotherapeutics Stock

by  •  • Comments Off on MLTX: MoonLake Immunotherapeutics Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 2,752.74
Enterprise Value ($M) 2,384.39
Book Value ($M) 495.50
Book Value / Share 7.86
Price / Book 5.56
NCAV ($M) 489.60
NCAV / Share 7.76
Price / NCAV 5.62

Profitability (mra)
Return on Invested Capital (ROIC) -0.16
Return on Assets (ROA) -0.15
Return on Equity (ROE) -0.16

Liquidity (mrq)
Quick Ratio 25.51
Current Ratio 25.51

Balance Sheet (mrq) ($M)
Current Assets 512.32
Assets 518.21
Liabilities 22.71
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
11-12 13G/A Fmr Llc 7.86 28.42
10-08 13D/A Biotechnology Value Fund L P 31.40 -9.19
02-14 13G/A Chen Bihua 14.17 23.24
02-14 13G/A Citadel Advisors Llc 3.40

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPO
2024-08-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PU
2024-05-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT P
2024-05-07 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (MARK ONE) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRAN
2024-02-29 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (MARK ONE) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUA

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-02-04 59,470 232,650 25.56
2025-02-03 62,705 263,462 23.80
2025-01-31 70,248 261,668 26.85
2025-01-30 102,576 297,648 34.46

(click for more detail)

Similar Companies
ME – 23andMe Holding Co. MEIP – MEI Pharma, Inc.
MIRA – MIRA Pharmaceuticals, Inc. MNPR – Monopar Therapeutics Inc.
MRKR – Marker Therapeutics, Inc.


Financial data and stock pages provided by
Fintel.io